These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36339206)

  • 1. Mental health and chest CT scores mediate the relationship between COVID-19 vaccination status and seroconversion time: A cross-sectional observational study in B.1.617.2 (Delta) infection patients.
    Zhang W; Chen Q; Dai J; Lu J; Li J; Yi Y; Fu L; Li X; Liu J; Liufu J; Long C; Zhang B
    Front Public Health; 2022; 10():974848. PubMed ID: 36339206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of inactivated COVID-19 vaccines on lung injury in B.1.617.2 (Delta) variant-infected patients.
    Lai M; Wang K; Ding C; Yin Y; Lin X; Xu C; Hu Z; Peng Z
    Ann Clin Microbiol Antimicrob; 2023 Mar; 22(1):22. PubMed ID: 36944961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical features of children with coronavirus disease 2019 Delta variant infection after vaccination with inactivated SARS-CoV-2 vaccine].
    Su H; Zhang X; Duan FY; Ren XQ; Yan YB; Ding Y
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Jul; 24(7):742-747. PubMed ID: 35894187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of inactivated COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China.
    Hu Z; Tao B; Li Z; Song Y; Yi C; Li J; Zhu M; Yi Y; Huang P; Wang J
    Int J Infect Dis; 2022 Mar; 116():204-209. PubMed ID: 35065255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los Angeles County, California, May 1-July 25, 2021.
    Griffin JB; Haddix M; Danza P; Fisher R; Koo TH; Traub E; Gounder P; Jarashow C; Balter S
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1170-1176. PubMed ID: 34437525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers].
    Şenol Akar Ş; Akçalı S; Özkaya Y; Gezginci FM; Cengiz Özyurt B; Deniz G; Karadağ Yalçın F; Özer D; Dündar Erbay P; Eser E
    Mikrobiyol Bul; 2021 Oct; 55(4):519-538. PubMed ID: 34666653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial comparative analysis of pulmonary involvement on HRCT between vaccinated and non-vaccinated subjects of COVID-19.
    Verma A; Kumar I; Singh PK; Ansari MS; Singh HA; Sonkar S; Prakash A; Ojha R; Shukla RC
    Eur Radiol; 2022 Jun; 32(6):4275-4283. PubMed ID: 35022810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of CT signs, radiomic features and clinical characteristics for delta variant COVID-19 patients with different vaccination status.
    Wei H; Shao Z; Tai J; Fu F; Lv C; Guo Z; Wu Y; Chen L; Bai Y; Wu Q; Yu X; Mu X; Shao F; Wang M
    BMC Med Imaging; 2022 Nov; 22(1):209. PubMed ID: 36447133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chest CT features of COVID-19 in vaccinated versus unvaccinated patients: use of CT severity score and outcome analysis.
    Masci GM; Izzo A; Bonito G; Marchitelli L; Guiducci E; Ciaglia S; Lucchese S; Corso L; Valenti A; Malzone L; Pasculli P; Ciardi MR; La Torre G; Galardo G; Alessandri F; Vullo F; Manganaro L; Iafrate F; Catalano C; Ricci P
    Radiol Med; 2023 Aug; 128(8):934-943. PubMed ID: 37354309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
    Ma C; Sun W; Tang T; Jia M; Liu Y; Wan Y; Han J; Rodewald L; Li J; Song Y; Wang Y; Wu D; Wang F; Zheng H; Tang L; Gao GF; Yin Z; An Z
    Vaccine; 2022 May; 40(20):2869-2874. PubMed ID: 35400561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study.
    Chia PY; Ong SWX; Chiew CJ; Ang LW; Chavatte JM; Mak TM; Cui L; Kalimuddin S; Chia WN; Tan CW; Chai LYA; Tan SY; Zheng S; Lin RTP; Wang L; Leo YS; Lee VJ; Lye DC; Young BE
    Clin Microbiol Infect; 2022 Apr; 28(4):612.e1-612.e7. PubMed ID: 34826623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Vaccination and the Omicron Variant on COVID-19-related Chest CT Findings: A Multicenter Study.
    Crombé A; Bensid L; Seux M; Fadli D; Arnaud F; Benhamed A; Banaste N; Gorincour G
    Radiology; 2023 May; 307(3):e222730. PubMed ID: 36880948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Seroconversion in Response to Infection and Vaccination: a Time Series Local Study in Brazil.
    Huergo LF; Paula NM; Gonçalves ACA; Kluge CHS; Marins PHSA; Camargo HSC; Sant'Ana TP; Farias LRP; Aldrighi JD; Lima ÊS; Jacotenski GT; Vargas LR; Costa G; Weissheimer KV; Nazário MG; Teixeira KN; Conzentino MS
    Microbiol Spectr; 2022 Aug; 10(4):e0102622. PubMed ID: 35770982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of seroconversion after coronavirus disease 2019 vaccination.
    Chiarella SE; Jenkins SM; Smith CY; Prasad V; Shakuntulla F; Ahluwalia V; Iyer VN; Theel ES; Joshi AY
    Ann Allergy Asthma Immunol; 2022 Aug; 129(2):189-193. PubMed ID: 35640775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thoracic imaging tests for the diagnosis of COVID-19.
    Salameh JP; Leeflang MM; Hooft L; Islam N; McGrath TA; van der Pol CB; Frank RA; Prager R; Hare SS; Dennie C; Spijker R; Deeks JJ; Dinnes J; Jenniskens K; Korevaar DA; Cohen JF; Van den Bruel A; Takwoingi Y; van de Wijgert J; Damen JA; Wang J; ; McInnes MD
    Cochrane Database Syst Rev; 2020 Sep; 9():CD013639. PubMed ID: 32997361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breakthrough COVID-19 Infection During the Delta Variant Dominant Period: Individualized Care Based on Vaccination Status Is Needed.
    Lee CM; Lee E; Park WB; Choe PG; Song KH; Kim ES; Park SW
    J Korean Med Sci; 2022 Aug; 37(32):e252. PubMed ID: 35971766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.
    Becerril-Gaitan A; Vaca-Cartagena BF; Ferrigno AS; Mesa-Chavez F; Barrientos-Gutiérrez T; Tagliamento M; Lambertini M; Villarreal-Garza C
    Eur J Cancer; 2022 Jan; 160():243-260. PubMed ID: 34794855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.